Santarus To Present Phase III Data For Rifamycin SV MMX In Travelers' Diarrhea

(RTTNews) - Santarus Inc. (SNTS) announced that new data from its Phase III clinical study with the investigational drug rifamycin SV MMX in patients with travelers' diarrhea will be featured in a poster presentation at IDWeek in San Francisco at the Moscone Center (Poster Hall C) from 12:30 p.m. to 2:00 p.m. Pacific Time on Saturday, October 5, 2013.

"The data from this clinical study indicate that rifamycin SV MMX significantly shortened the duration of travelers' diarrhea and was well tolerated, with adverse events similar to that of placebo in the study. In addition, rifamycin SV MMX demonstrated broad activity, and of interest was the possible activity against invasive pathogens," said Herbert DuPont, principal investigator and lead author of the poster.

The company has previously announced that the Phase III study met the primary endpoint of reducing the time to last unformed stool or TLUS in the intent-to-treat or ITT population.